<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268229</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-6441</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-6441</secondary_id>
    <nct_id>NCT00268229</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the&#xD;
      enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and&#xD;
      cytarabine, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving imatinib mesylate together with daunorubicin&#xD;
      and cytarabine may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate&#xD;
      when given together with daunorubicin and cytarabine in treating patients with relapsed acute&#xD;
      myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and recommended phase II dose of imatinib&#xD;
           mesylate in combination with daunorubicin hydrochloride and cytarabine in patients with&#xD;
           relapsed acute myeloid leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the non-dose-limiting toxicities associated with this regimen in these patients.&#xD;
&#xD;
        -  Determine any preliminary evidence of clinical activity of this regimen in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of imatinib mesylate.&#xD;
&#xD;
      Patients receive daunorubicin IV on days 1-3 and cytarabine IV continuously on days 1-7.&#xD;
      Patients also receive oral imatinib mesylate once daily beginning on day 1 and continuing&#xD;
      until disease progression or unacceptable toxicity. Patients with persistent leukemia on day&#xD;
      14 bone marrow biopsy but ≥ 50% reduction in bone marrow blasts receive 5 more days of&#xD;
      cytarabine and 2 more days of daunorubicin while continuing imatinib mesylate.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at&#xD;
      the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of imatinib mesylate at one year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-dose limiting toxicities associated with imatinib mesylate at one year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>300 mg/m2/day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>45 mg/m2/day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>dose escalation (300 mg/day to 800 mg/day).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Bone marrow biopsy confirming acute myeloid leukemia (AML)&#xD;
&#xD;
               -  No M3 AML&#xD;
&#xD;
          -  Patient must have relapsed to standard chemotherapy&#xD;
&#xD;
               -  Patients who relapse within six months of response to treatment or those who&#xD;
                  never responded to an anthracycline/cytarabine combination will be excluded&#xD;
&#xD;
          -  At least 20% of peripheral blood or bone marrow blasts positive for c-kit&#xD;
&#xD;
          -  No evidence of leptomeningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Liver enzymes (AST and ALT) and total bilirubin ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Serum creatinine ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  No New York Heart Association grade III or IV cardiac problems&#xD;
&#xD;
               -  Defined as congestive heart failure or myocardial infraction within the past 6&#xD;
                  months&#xD;
&#xD;
          -  No known chronic liver disease (i.e., chronic active hepatitis and cirrhosis)&#xD;
&#xD;
          -  No serious or poorly controlled medical conditions that could be exacerbated by the&#xD;
             treatment or would seriously complicate compliance with this study&#xD;
&#xD;
          -  No other active primary malignancy unless it is not currently clinically significant&#xD;
             and does not require active intervention&#xD;
&#xD;
          -  No history of HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No significant history of noncompliance to medical regimens or inability to grant&#xD;
             reliable informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Previous treatment-related toxicities should be resolved&#xD;
&#xD;
          -  No other investigational agents within the past 28 days&#xD;
&#xD;
          -  No chemotherapy within the past 4 weeks&#xD;
&#xD;
               -  6 weeks for nitrosourea or mitomycin C&#xD;
&#xD;
          -  No major surgery within the past 4 weeks&#xD;
&#xD;
          -  No concurrent use of the following drugs is allowed: ketoconazole, dilantin,&#xD;
             itraconazole, erythromycin, clarithromycin, dexamethasone, rifampin, tegretol,&#xD;
             phenobarbital, Hypericum perforatum (St. John's wort), cyclosporine, pimozide,&#xD;
             warfarin, certain HMG-CoA reductase inhibitors, traizolo-benzodiazepines, or&#xD;
             dihydropyridine calcium channel blockers&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy and biologic agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  Concurrent medications known to be metabolized by cytochrome p450 enzymes are allowed&#xD;
&#xD;
          -  No therapeutic anticoagulation with warfarin will be permitted in patients&#xD;
             participating in this study&#xD;
&#xD;
               -  Therapeutic anticoagulation may be accomplished using low-molecular weight&#xD;
                  heparin&#xD;
&#xD;
               -  Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed&#xD;
&#xD;
          -  No concurrent routine use of systemic corticosteroid therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjali Advani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

